MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Koneczny, Inga ^a   Cossins, Judith ^a   Waters, Patrick ^a   Beeson, David ^a   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; CELL PROTEIN; CHOLINERGIC RECEPTOR; ENZYME ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; MUSCLE SPECIFIC TYROSINE KINASE; MUSCLE SPECIFIC TYROSINE KINASE ANTIBODY; PROTEIN DOK7; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; LRP4 PROTEIN, HUMAN; MUSK PROTEIN, HUMAN; PROTEIN BINDING;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CELL STRAIN HEK293; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INHIBITION KINETICS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; MYOTUBE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; PRESCHOOL CHILD; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR DENSITY; YOUNG ADULT; IMMUNOLOGY; METABOLISM;

ADOLESCENT; ADULT; AGRIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; LDL-RECEPTOR RELATED PROTEINS; MALE; MYASTHENIA GRAVIS; PROTEIN BINDING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; YOUNG ADULT;

EID: 84892393537     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080695     Document Type: Article

References (57)

1. Punga AR, Ruegg MA (2012) Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases. Curr Opin Pharmacol 12: 340-346. doi:10.1016/j.coph.2012.02.002. PubMed: 22365504.
2. Spillane J, Higham E, Kullmann DM (2012) Myasthenia gravis. BMJ 345: e8497. doi:10.1136/bmj.e8497. PubMed: 23261848.
3. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A et al. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368. doi:10.1038/85520. PubMed: 11231638.
4. Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69: 418-422. doi:10.1002/ana.22312. PubMed: 21387385.
5. Cossins J, Belaya K, Zoltowska K, Koneczny I, Maxwell S et al. (2012) The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 1275: 123-128. doi:10.1111/j.1749-6632.2012.06833.x. PubMed: 23278587.
6. DeChiara TM, Bowen DC, Valenzuela DM, Simmons MV, Poueymirou WT et al. (1996) The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85: 501-512. doi:10.1016/S0092-8674(00)81251-9. PubMed: 8653786.
7. McMahan UJ (1990) The agrin hypothesis. Cold Spring Harb Symp Quant Biol 55: 407-418. doi:10.1101/SQB.1990.055.01.041. PubMed: 1966767.
8. Okada K, Inoue A, Okada M, Murata Y, Kakuta S et al. (2006) The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312: 1802-1805. doi:10.1126/science.1127142. PubMed: 16794080.
9. Inoue A, Setoguchi K, Matsubara Y, Okada K, Sato N et al. (2009) Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation. Sci Signal 2: ra7 PubMed: 19244212.
10. Gautam M, Noakes PG, Mudd J, Nichol M, Chu GC et al. (1995) Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature 377: 232-236. doi:10.1038/377232a0. PubMed: 7675108.
11. Gautam M, Noakes PG, Moscoso L, Rupp F, Scheller RH et al. (1996) Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85: 525-535. doi:10.1016/S0092-8674(00)81253-2. PubMed: 8653788.
12. Ghazanfari N, Fernandez KJ, Murata Y, Morsch M, Ngo ST et al. (2011) Muscle specific kinase: organiser of synaptic membrane domains. Int J Biochem Cell Biol 43: 295-298. doi:10.1016/j.biocel.2010.10.008. PubMed: 20974278.
13. Koneczny I, Cossins J, Vincent A (2013) The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat. PubMed: 23458718
14. Viegas S, Jacobson L, Waters P, Cossins J, Jacob S et al. (2012) Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 234: 506-512. doi:10.1016/j.expneurol.2012.01.025. PubMed: 22326541.
15. Jha S, Xu K, Maruta T, Oshima M, Mosier DR et al. (2006) Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 175: 107-117. doi:10.1016/j.jneuroim.2006.03.016. PubMed: 16697051.
16. Xu K, Jha S, Hoch W, Dryer SE (2006) Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 143: 655-659. doi:10.1016/j.neuroscience.2006.09.022. PubMed: 17081697.
17. Cole RN, Reddel SW, Gervásio OL, Phillips WD (2008) Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63: 782-789. doi:10.1002/ana.21371. PubMed: 18384168.
18. ter Beek WP, Martínez-Martínez P, Losen M, de Baets MH, Wintzen AR et al. (2009) The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am J Pathol 175: 1536-1544. doi:10.2353/ajpath.2009.090040. PubMed: 19745065.
19. Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR et al. (2012) Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain : J Neurol 135: 1081-1101. doi:10.1093/brain/aws025. PubMed: 22396395.
20. Cole RN, Ghazanfari N, Ngo ST, Gervásio OL, Reddel SW et al. (2010) Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 588: 3217-3229. doi:10.1113/jphysiol.2010.190298. PubMed: 20603331.
21. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R et al. (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55: 580-584. doi:10.1002/ana.20061. PubMed: 15048899.
22. Ferns MJ, Campanelli JT, Hoch W, Scheller RH, Hall Z (1993) The ability of agrin to cluster AChRs depends on alternative splicing and on cell surface proteoglycans. Neuron 11: 491-502. doi:10.1016/0896-6273(93)90153-I. PubMed: 8398142.
23. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H et al. (2006) Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116: 1016-1024. doi:10.1172/JCI21545. PubMed: 16557298.
24. Farrugia ME, Bonifati DM, Clover L, Cossins J, Beeson D et al. (2007) Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 185: 136-144. doi:10.1016/j.jneuroim. 2007.01.010. PubMed: 17335909.
25. Mori S, Yamada S, Kubo S, Chen J, Matsuda S et al. (2012) Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J Neuroimmunol.
26. Cossins J, Liu WW, Belaya K, Maxwell S, Oldridge M et al. (2012) The spectrum of mutations that underlie the neuromuscular junction synaptopathy in DOK7 congenital myasthenic syndrome. Hum Mol Genet 21: 3765-3775. doi:10.1093/hmg/dds198. PubMed: 22661499.
27. Beeson D, Higuchi O, Palace J, Cossins J, Spearman H et al. (2006) Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 313: 1975-1978. doi:10.1126/science.1130837. PubMed: 16917026.
28. Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR et al. (2008) Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 195: 151-156. doi:10.1016/j.jneuroim.2008. 01.013. PubMed: 18384886.
29. Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F et al. (2006) Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67: 505-507. doi:10.1212/01.wnl.0000228225.23349.5d. PubMed: 16894117.
30. Aucouturier P, Danon F, Daveau M, Guillou B, Sabbah A et al. (1984) Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J Immunol Methods 74: 151-162. doi:10.1016/0022-1759(84) 90376-4. PubMed: 6438233.
31. Nirula A, Glaser SM, Kalled SL, Taylor FR (2011) What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 23: 119-124. doi:10.1097/BOR.0b013e3283412fd4. PubMed: 21124094.
32. Aalberse RC, Stapel SO, Schuurman J, Rispens T (2009) Immunoglobulin G4: an odd antibody. Clin Exp Allergy 39: 469-477. doi:10.1111/j.1365-2222.2009. 03207.x. PubMed: 19222496.
33. van der Zee JS, van Swieten P, Aalberse RC (1986) Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 137: 3566-3571. PubMed: 3782791.
34. Margni RA, Binaghi RA (1988) Nonprecipitating asymmetric antibodies. Annu Rev Immunol 6: 535-554. doi:10.1146/annurev.iy.06.040188.002535. PubMed: 3289577.
35. Lessof MH, Sobotka AK, Lichtenstein LM (1978) Effects of passive antibody in bee venom anaphylaxis. Johns Hopkins Med J 142: 1-7. PubMed: 75280.
36. Kemeny DM, MacKenzie-Mills M, Harries MG, Youlten LJ, Lessof MH (1983) Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens. J Allergy Clin Immunol 72: 376-385. doi:10.1016/0091-6749(83)90503-1. PubMed: 6619452.
37. Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM et al. (2008) Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135: 334-342. doi:10.1016/j.cell.2008.10.002. PubMed: 18848351.
38. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC et al. (2008) LRP4 serves as a coreceptor of agrin. Neuron 60: 285-297. doi:10.1016/j.neuron.2008.10.006. PubMed: 18957220.
39. Zhang W, Coldefy AS, Hubbard SR, Burden SJ (2011) Agrin Binds to the N-terminal Region of Lrp4 Protein and Stimulates Association between Lrp4 and the First Immunoglobulin-like Domain in Muscle-specific Kinase (MuSK). J Biol Chem 286: 40624-40630. doi:10.1074/jbc.M111.279307. PubMed: 21969364.
40. Ohno K (2012) Anti-MuSK antibodies in myasthenia gravis block binding of collagen Q to MuSK. Rinsho shinkeigaku =. Clin Neurol 52: 1306-1308.
41. Vincent A, Whiting PJ, Schluep M, Heidenreich F, Lang B et al. (1987) Antibody heterogeneity and specificity in myasthenia gravis. Ann N Y Acad Sci 505: 106-120. doi:10.1111/j.1749-6632.1987.tb51286.x. PubMed: 2446546.
42. Herbst R, Burden SJ (2000) The juxtamembrane region of MuSK has a critical role in agrin-mediated signaling. EMBO J 19: 67-77. doi:10.1093/emboj/19.1.67. PubMed: 10619845.
43. Burden SJ, Yumoto N, Zhang W (2013) The Role of MuSK in Synapse Formation and Neuromuscular Disease. Cold Spring Harb Perspect Biol 5.
44. Mori S, Kubo S, Akiyoshi T, Yamada S, Miyazaki T et al. (2012) Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 180: 798-810. doi:10.1016/j.ajpath.2011.10.031. PubMed: 22142810.
45. Takamori M, Nakamura T, Motomura M (2013) Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis. J Neuroimmunol 254: 183-186. doi:10.1016/j.jneuroim.2012.09.001. PubMed: 22999188.
46. Zhang B, Liang C, Bates R, Yin Y, Xiong WC et al. (2012) Wnt proteins regulate acetylcholine receptor clustering in muscle cells. Mol Brain 5: 7. doi:10.1186/1756-6606-5-7. PubMed: 22309736.
47. Gordon LR, Gribble KD, Syrett CM, Granato M (2012) Initiation of synapse formation by Wnt-induced MuSK endocytosis. Development 139: 1023-1033. doi:10.1242/dev.071555. PubMed: 22318632.
48. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS et al. (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133: 349-361. doi:10.1093/brain/awp309. PubMed: 20047900.
49. Leite MI, Jacob S, Viegas S, Cossins J, Clover L et al. (2008) IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain : J Neurol 131: 1940-1952. doi:10.1093/brain/awn092. PubMed: 18515870.
50. Tüzün E, Yilmaz V, Parman Y, Oflazer P, Deymeer F et al. (2011) Increased complement consumption in MuSK-antibody-positive myasthenia gravis patients. Med Princ Practice Int J Kuwait University Health Sci Cent 20: 581-583. doi:10.1159/000330031. PubMed: 21986021.
51. Punga AR, Maj M, Lin S, Meinen S, Rüegg MA (2011) MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity. Eur J Neurosci 33: 890-898. doi:10.1111/j.1460-9568.2010.07569.x. PubMed: 21255125.
52. Keung B, Robeson KR, Dicapua DB, Rosen JB, O'Connor KC et al. (2013) Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry. PubMed: 23761915
53. Khosroshahi A, Bloch DB, Deshpande V, Stone JH (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62: 1755-1762. doi:10.1002/art.27435. PubMed: 20191576.
54. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB et al. (2012) Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 91: 57-66. doi:10.1097/MD. 0b013e3182431ef6. PubMed: 22210556.
55. Xu D, Staedman A, Zhang L (2013) CD20 Antibody Primes B Lymphocytes for Type I Interferon Production. PLOS ONE 8: e67900. doi:10.1371/journal.pone. 0067900. PubMed: 23874371.
56. Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A (2012) Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 90: 498-504. doi:10.1038/icb.2012.10. PubMed: 22430248.
57. Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R et al. (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78: 189-193. doi:10.1212/WNL. 0b013e3182407982. PubMed: 22218276.